Trials / Withdrawn
WithdrawnNCT01273402
Study of TF2 Carcinoembryonic Antigen (CEA) Antibody in Patients With Metastatic Colorectal Cancer
Pretargeted Radioimmunotherapy of Colorectal Cancer: A Phase I Study to Determine Dose-limiting Toxicity and Maximum Tolerated Dose of an Anti-CEACAM5 bsMAb-pretargeted 90Y-hapten-peptide
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Gilead Sciences · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is being done to select an appropriate TF2 bsMAb dose suitable for pretargeting the 111In/90Y-labeled hapten-peptide (IMP-288). Eligible patients will receive a fixed dose of 90Y-IMP-288 4 days after the TF2 antibody injection. Two different dose levels of TF2 will be studied in the first part. Once an appropriate TF2 dose is selected based on information learned from the first 2 dose levels, patients will be enrolled onto several different increasing dose levels of 90Y-IMP-288.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TF2/IMP288 | TF2 is administered 4 days prior to radiolabeled IMP288. Each are given weekly for 2 weeks. |
Timeline
- Start date
- 2011-02-01
- Primary completion
- 2013-02-01
- Completion
- 2018-08-01
- First posted
- 2011-01-10
- Last updated
- 2021-08-16
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01273402. Inclusion in this directory is not an endorsement.